GCM
VKTX icon

Generation Capital Management’s Viking Therapeutics VKTX Stock Holding History

Generation Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$378K Buy
11,630
+2,000
+21% +$64.3K 0.28% 59
2025
Q4 		$339K Hold
9,630
– – 0.22% 70
2025
Q3 		$253K Hold
9,630
– – 0.18% 70
2025
Q2 		$255K Buy
+9,630
New +$254K 0.2% 68

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Generation Capital Management's VKTX Position: Q1 2026 in Review

Generation Capital Management increased its Viking Therapeutics (VKTX) stake by 21% in Q1 2026, buying an estimated $64.3K and bringing the position to 11,630 shares worth $378K. The position accounts for 0.28% of the portfolio, ranked #59.

Generation Capital Management first reported a position in VKTX in Q2 2025 and has held it in 4 quarters since. 412 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Generation Capital Management held 11,630 shares of Viking Therapeutics worth $378K as of Q1 2026.
  • Generation Capital Management bought 2,000 Viking Therapeutics shares in Q1 2026, an estimated $64.3K.
  • Viking Therapeutics made up 0.28% of Generation Capital Management's portfolio in Q1 2026, its #59 holding.
  • Generation Capital Management first reported a position in Viking Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 412 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Generation Capital Management's 13F filing for Q1 2026, filed 8 May 2026.